Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
by GlobeNewswire
Oct 15, 2024 4:40 am
Data presentations highlight the results for FILSPARI®(sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies
Late-breaking presentation details outcomes of sparsentan's effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis